Oleh Hornykiewicz -- Melvin Yahr (1917-2004). An appreciation -- Melvin D. Yahr, 1917-2004. A personal recollection -- Melvin D. Yahr, 1917-2004. A personal recollection -- Pathology -- The discovery of dopamine deficiency in the parkinsonian brain -- Synchronizing activity of basal ganglia and pathophysiology of Parkinson's disease -- Basal ganglia discharge abnormalities in Parkinson's disease -- Bad oscillations in Parkinson's disease -- Cortical muscle coupling in Parkinson's disease (PD) bradykinesia -- GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons -- The engrailed transcription factors and the mesencephalic dopaminergic neurons -- The role of Pitx3 in survival of midbrain dopaminergic neurons -- Genetic analysis of dopaminergic system development in zebrafish -- Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease -- The nigrostriatal DA pathway and Parkinson's disease -- Relationship between axonal collateralization and neuronal degeneration in basal ganglia -- Pathology associated with sporadic Parkinson's disease - where does it end? -- Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease -- A short overview on the role of ?-synuclein and proteasome in experimental models of Parkinson's disease -- The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help? -- Iron and neuromelanin -- New face of neuromelanin -- The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells -- Potential sources of increased iron in the substantia nigra of parkinsonian patients -- Iron and Friedreich ataxia -- Genetics -- Nongenetic causes of Parkinson's disease -- Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae? -- CYP450, genetics and Parkinson's disease: gene × environment interactions hold the key -- Unique cytochromes P450 in human brain: implication in disease pathogenesis -- Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity -- Nicotine induces brain CYP enzymes: relevance to Parkinson's disease -- Genetic causes of Parkinson's disease: extending the pathway -- Progress in familial Parkinson's disease -- Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins -- Parkin and defective ubiquitination in Parkinson's disease -- PINK-1 and DJ-1 - new genes for autosomal recessive Parkinson's disease -- Clinical and pathologic features of families with LRRK2-associated Parkinson's disease -- Molecular genetic findings in LRRK2 American, Canadian and German families -- Imaging -- Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort -- Neuroimaging in Parkinson's disease -- Transcranial sonography in the early and differential diagnosis of Parkinson's disease -- Models -- How to judge animal models of Parkinson's disease in terms of neuroprotection -- Limitations of cellular models in Parkinson's disease research -- The Rotenone model of Parkinsonism - the five years inspection -- Controversies on new animal models of Parkinson's disease Pro and Con: the rotenone model of Parkinson's disease (PD) -- Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum -- ?-Synuclein overexpression model -- Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies -- Clinical approaches -- What's new? Clinical progression and staging of Parkinson's disease -- Parkinson's disease: premotor clinico-pathological correlations -- Detection of preclinical Parkinson's disease along the olfactory trac(t) -- The clinical approach to gait disturbances in Parkinson's disease; maintaining independent mobility -- Getting around and communicating with the environment: visual cognition and language in Parkinson's disease -- Cardiovascular aspects of Parkinson disease -- Multiple system atrophy and autonomic failure -- Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview -- Sleep and wakefulness disturbances in Parkinson's disease -- Neuroinflammation -- Parkinson's disease dementia: what's in a Lewy body? -- Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10 -- Role of cytokines in inflammatory process in Parkinson's disease -- Neurosurgery -- Surgical therapy for Parkinson's disease -- Deep brain stimulation for the treatment of Parkinson's disease -- Deep brain stimulation in Parkinson's disease patients: biochemical evidence -- Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so? -- L-Dopa -- Placebo effect and dopamine release -- A new look at levodopa based on the ELLDOPA study -- Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations -- Neuroprotection -- Concerning neuroprotective therapy for Parkinson's disease -- Triggering endogenous neuroprotective mechanisms in Parkinson's disease: studies with a cellular model -- Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression -- M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease -- Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety -- Other treatment strategies -- Anti-apoptotic gene therapy in Parkinson's disease -- The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors -- Dystonia -- Pathophysiology of dystonia -- Genetics of dystonia.